vs
Cardio Diagnostics Holdings, Inc.（CDIO）与NEOGEN CORP（NEOG）财务数据对比。点击上方公司名可切换其他公司
NEOGEN CORP的季度营收约是Cardio Diagnostics Holdings, Inc.的63204.2倍（$224.7M vs $3.6K）。NEOGEN CORP同比增速更快（-2.8% vs -21.2%）。NEOGEN CORP自由现金流更多（$7.8M vs $-5.9M）。过去两年NEOGEN CORP的营收复合增速更高（-0.9% vs -52.8%）
Cardio Diagnostics Holdings, Inc.是一家专注于精准心血管医疗的企业，开发并商业化整合遗传与表观遗传技术的诊断检测产品，可早期识别冠心病、心力衰竭等心血管疾病，主要服务美国市场的医疗机构、临床实验室与患者。
Neogen Corporation是一家1982年成立、总部位于美国密歇根州兰辛的跨国食品安全企业，专注提供各类检测试剂盒及相关产品，用于筛查食品中的有害成分。目前业务覆盖美国、加拿大、英国、欧洲部分地区、墨西哥、巴西、印度、中国等多个国家，旗下拥有超100款药物检测试剂盒产品，可检测约300种相关违禁物质。
CDIO vs NEOG — 直观对比
营收规模更大
NEOG
是对方的63204.2倍
$3.6K
营收增速更快
NEOG
高出18.4%
-21.2%
自由现金流更多
NEOG
多$13.7M
$-5.9M
两年增速更快
NEOG
近两年复合增速
-52.8%
损益表 — Q4 2025 vs Q2 2026
| 指标 | | |
|---|---|---|
| 营收 | $3.6K | $224.7M |
| 净利润 | — | $-15.9M |
| 毛利率 | — | 47.5% |
| 营业利润率 | — | -2.4% |
| 净利率 | — | -7.1% |
| 营收同比 | -21.2% | -2.8% |
| 净利润同比 | 3.6% | 96.5% |
| 每股收益（稀释后） | — | $-0.07 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收CDIONEOG
| Q4 25 | $3.6K | $224.7M | ||
| Q3 25 | $2.9K | $209.2M | ||
| Q2 25 | $7.5K | $225.4M | ||
| Q1 25 | $940 | $221.0M | ||
| Q4 24 | $4.5K | $231.3M | ||
| Q3 24 | $6.6K | $217.0M | ||
| Q2 24 | $7.9K | $236.8M | ||
| Q1 24 | $15.9K | $228.8M |
净利润CDIONEOG
| Q4 25 | — | $-15.9M | ||
| Q3 25 | $-1.7M | $36.3M | ||
| Q2 25 | $-1.7M | $-612.3M | ||
| Q1 25 | $-1.6M | $-10.9M | ||
| Q4 24 | — | $-456.3M | ||
| Q3 24 | $-1.4M | $-12.6M | ||
| Q2 24 | $-1.3M | $-5.4M | ||
| Q1 24 | $-4.2M | $-2.0M |
毛利率CDIONEOG
| Q4 25 | — | 47.5% | ||
| Q3 25 | — | 45.4% | ||
| Q2 25 | — | 41.2% | ||
| Q1 25 | — | 49.9% | ||
| Q4 24 | — | 49.0% | ||
| Q3 24 | — | 48.4% | ||
| Q2 24 | — | 47.9% | ||
| Q1 24 | — | 51.1% |
营业利润率CDIONEOG
| Q4 25 | — | -2.4% | ||
| Q3 25 | -59950.9% | -7.7% | ||
| Q2 25 | -22457.5% | -271.1% | ||
| Q1 25 | -173463.8% | 2.4% | ||
| Q4 24 | — | -197.8% | ||
| Q3 24 | -21412.9% | 1.0% | ||
| Q2 24 | -16295.6% | 5.5% | ||
| Q1 24 | -26105.3% | 5.3% |
净利率CDIONEOG
| Q4 25 | — | -7.1% | ||
| Q3 25 | -60053.8% | 17.4% | ||
| Q2 25 | -22517.7% | -271.6% | ||
| Q1 25 | -173943.0% | -4.9% | ||
| Q4 24 | — | -197.3% | ||
| Q3 24 | -21467.6% | -5.8% | ||
| Q2 24 | -16365.9% | -2.3% | ||
| Q1 24 | -26140.0% | -0.9% |
每股收益（稀释后）CDIONEOG
| Q4 25 | — | $-0.07 | ||
| Q3 25 | $-0.98 | $0.17 | ||
| Q2 25 | $-0.97 | $-2.82 | ||
| Q1 25 | $-0.97 | $-0.05 | ||
| Q4 24 | — | $-2.10 | ||
| Q3 24 | $-1.73 | $-0.06 | ||
| Q2 24 | $-1.71 | $-0.02 | ||
| Q1 24 | $-5.93 | $-0.01 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | — | $145.3M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $7.0M | $2.1B |
| 总资产 | $7.8M | $3.4B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资CDIONEOG
| Q4 25 | — | $145.3M | ||
| Q3 25 | — | $138.9M | ||
| Q2 25 | — | $129.0M | ||
| Q1 25 | — | $127.7M | ||
| Q4 24 | — | $140.2M | ||
| Q3 24 | — | $120.5M | ||
| Q2 24 | — | $170.9M | ||
| Q1 24 | — | $168.4M |
股东权益CDIONEOG
| Q4 25 | $7.0M | $2.1B | ||
| Q3 25 | $8.2M | $2.1B | ||
| Q2 25 | $9.7M | $2.1B | ||
| Q1 25 | $11.4M | $2.7B | ||
| Q4 24 | $9.6M | $2.7B | ||
| Q3 24 | $3.7M | $3.1B | ||
| Q2 24 | $3.1M | $3.1B | ||
| Q1 24 | $3.0M | $3.1B |
总资产CDIONEOG
| Q4 25 | $7.8M | $3.4B | ||
| Q3 25 | $8.8M | $3.4B | ||
| Q2 25 | $10.4M | $3.4B | ||
| Q1 25 | $12.3M | $4.0B | ||
| Q4 24 | $10.6M | $4.1B | ||
| Q3 24 | $4.5M | $4.5B | ||
| Q2 24 | $4.0M | $4.5B | ||
| Q1 24 | $4.3M | $4.6B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-5.7M | $19.4M |
| 自由现金流经营现金流 - 资本支出 | $-5.9M | $7.8M |
| 自由现金流率自由现金流/营收 | -166361.5% | 3.5% |
| 资本支出强度资本支出/营收 | 5269.1% | 5.2% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $-10.5M | $-18.5M |
8季度趋势，按日历期对齐
经营现金流CDIONEOG
| Q4 25 | $-5.7M | $19.4M | ||
| Q3 25 | $-1.4M | $10.9M | ||
| Q2 25 | $-1.6M | $16.4M | ||
| Q1 25 | $-1.4M | $19.5M | ||
| Q4 24 | $-5.0M | $40.3M | ||
| Q3 24 | $-1.2M | $-17.9M | ||
| Q2 24 | $-1.2M | $26.7M | ||
| Q1 24 | $-1.2M | $-30.2M |
自由现金流CDIONEOG
| Q4 25 | $-5.9M | $7.8M | ||
| Q3 25 | $-1.6M | $-13.1M | ||
| Q2 25 | $-1.6M | $349.0K | ||
| Q1 25 | $-1.4M | $-13.4M | ||
| Q4 24 | $-5.2M | $23.1M | ||
| Q3 24 | $-1.2M | $-56.3M | ||
| Q2 24 | $-1.4M | $2.5M | ||
| Q1 24 | $-1.3M | $-62.3M |
自由现金流率CDIONEOG
| Q4 25 | -166361.5% | 3.5% | ||
| Q3 25 | -54509.7% | -6.3% | ||
| Q2 25 | -21273.1% | 0.2% | ||
| Q1 25 | -149562.6% | -6.1% | ||
| Q4 24 | -115422.6% | 10.0% | ||
| Q3 24 | -17942.3% | -26.0% | ||
| Q2 24 | -17513.3% | 1.1% | ||
| Q1 24 | -7866.9% | -27.2% |
资本支出强度CDIONEOG
| Q4 25 | 5269.1% | 5.2% | ||
| Q3 25 | 5703.5% | 11.5% | ||
| Q2 25 | 250.1% | 7.1% | ||
| Q1 25 | 615.6% | 14.9% | ||
| Q4 24 | 4759.9% | 7.4% | ||
| Q3 24 | 353.3% | 17.7% | ||
| Q2 24 | 2133.4% | 10.2% | ||
| Q1 24 | 125.5% | 14.0% |
现金转化率CDIONEOG
| Q4 25 | — | — | ||
| Q3 25 | — | 0.30× | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
CDIO
暂无分部数据
NEOG
| Other | $109.2M | 49% |
| Bacterial And General Sanitation | $44.9M | 20% |
| Services | $25.7M | 11% |
| Natural Toxins And Allergens | $20.4M | 9% |
| Animal Care | $8.9M | 4% |
| Genomics Services | $6.3M | 3% |
| Biosecurity Products | $4.6M | 2% |
| Life Sciences | $1.4M | 1% |
